Sana Biotechnology advances cell and gene therapy pipeline toward 2026 clinical trials
Sana Biotechnology reported second quarter 2026 financial results and business highlights, ending June 30 with $160.5 million in cash, cash equivalents and marketable securities and an expected cash runway into mid-2027. The company raised aggregate net proceeds of $93.3 million in Q2 from at-the-ma
<p>Sana Biotechnology reported second quarter 2026 financial results and business highlights, ending June 30 with $160.5 million in cash, cash equivalents and marketable securities and an expected cash runway into mid-2027. The company raised aggregate net proceeds of $93.3 million in Q2 from at-the-ma</p>